case study

GrowthWorks Canadian Fund

Transaction Overview Rosetta Capital completed a secondary transaction involving debt and equity to secure a portfolio of US and Canadian life sciences assets from GrowthWorks, a Canadian fund manager. Selected exits from the portfolio include the sale of Gemin X to Cephalon, Ambit Pharmaceuticals to Daiichi Sankyo and Aegera to Pharmascience. All3 Exited Private Public …

GrowthWorks Canadian Fund Read More »

Karolinska Development

Transaction Overview In February 2013, Rosetta Capital completed a secondary transaction to acquire a portfolio of thirteen life sciences assets from Karolinska Development, the investment arm of Karolinska Institutet, a leading university in Sweden. The sale portfolio consists of holdings in Akinion Pharmaceuticals, Aprea Therapeutics, Axelar, Biosergen, Clanotech, Dilafor, Inhalation Sciences, NeoDynamics, NovaSAID, Pergamum, Promimic, …

Karolinska Development Read More »